Effects of high-amount-high-intensity exercise on in vivo platelet activation: Modulation by lipid peroxidation and AGE/RAGE axis

Thrombosis and Haemostasis

Volumn 110, Issue 6, 2013, Pages 1232-1240

  Santilli, Francesca ^a   Vazzana, Natale ^a   Iodice, Pierpaolo ^a   Lattanzio, Stefano ^a   Liani, Rossella ^a   Bellomo, Rosa Grazia ^a   Lessiani, Gianfranco ^a   Perego, Francesca ^b   Saggini, Raoul ^a   Davì, Giovanni ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Aerobic exercise; esRAGE; Oxidative stress; Platelet activation

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CD40 LIGAND; HIGH DENSITY LIPOPROTEIN; PADGEM PROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; DIETARY INTAKE; ENDURANCE TRAINING; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE; EXERCISE INTENSITY; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; LIPID PEROXIDATION; MALE; MASS FRAGMENTOGRAPHY; OXIDATIVE STRESS; PRIORITY JOURNAL; QUESTIONNAIRE; RADIOIMMUNOASSAY; THROMBOCYTE ACTIVATION; URINARY EXCRETION;

AEROBIC EXERCISE; ESRAGE; OXIDATIVE STRESS; PLATELET ACTIVATION;

AGED; BLOOD PLATELETS; CD40 LIGAND; EXERCISE; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; ISOPROSTANES; LIPID PEROXIDATION; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; OXIDATIVE STRESS; P-SELECTIN; PLATELET ACTIVATION; RECEPTORS, IMMUNOLOGIC; THROMBOXANE B2; THROMBOXANES;

EID: 84888414545     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-04-0295     Document Type: Article

References (60)

1. Thompson PD, Franklin BA, Balady GJ, et al. Exercise and acute cardiovascular events placing the risks into perspective: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Cardiology. Circulation 2007; 115: 2358-2368.
2. Blair SN, Kohl HW 3rd, Barlow CE, et al. Changes in physical fitness and allcause mortality. A prospective study of healthy and unhealthy men. J Am Med Assoc 1995; 273: 1093-1098.
3. Kokkinos P, Myers J, Faselis C, et al. Exercise capacity and mortality in older men: a 20-year follow-up study. Circulation 2010; 122: 790-797.
4. Leon AS, Connett J, Jacobs DR Jr, et al. Leisure-time physical activity levels and risk of coronary heart disease and death. The Multiple Risk Factor Intervention Trial. J Am Med Assoc 1987; 258: 2388-2395.
5. Paffenbarger RS Jr, Hyde RT, Wing AL, et al. Physical activity, all-cause mortality, and longevity of college alumni. N Engl J Med 1986; 314: 605-613.
6. Leon AS, Sanchez OA. Response of blood lipids to exercise training alone or combined with dietary intervention. Med Sci Sports Exerc 2001; 33(6 Suppl): S502-515; discussion S528-529.
7. Zoppini G, Targher G, Zamboni C, et al. Effects of moderate-intensity exercise training on plasma biomarkers of inflammation and endothelial dysfunction in older patients with type 2 diabetes. Nutr Metab Cardiovasc Dis 2006; 16: 543-549.
8. Kodama S, Tanaka S, Saito K, et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med 2007; 167: 999-1008.
9. Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002; 347: 1483-1492.
10. Kraus WE, Torgan CE, Duscha BD, et al. Studies of a targeted risk reduction intervention through defined exercise (STRRIDE). Med Sci Sports Exerc 2001; 33: 1774-1784.
11. Slentz CA, Houmard JA, Johnson JL, et al. Inactivity, exercise training and detraining, and plasma lipoproteins. STRRIDE: a randomized, controlled study of exercise intensity and amount. J Appl Physiol 2007; 103: 432-442.
12. Kestin AS, Ellis PA, Barnard MR, et al. Effect of strenuous exercise on platelet activation state and reactivity. Circulation 1993; 88: 1502-1511.
13. Li N, Wallén NH, Hjemdahl P. Evidence for prothrombotic effects of exercise and limited protection by aspirin. Circulation 1999; 100: 1374-1379.
14. Wang JS, Li YS, Chen JC, et al. Effects of exercise training and deconditioning on platelet aggregation induced by alternating shear stress in men. Arterioscler Thromb Vasc Biol 2005; 25: 454-460.
15. Thrall G, Lip GY. Exercise and the prothrombotic state: a paradox of cardiovascular prevention or an enhanced prothrombotic state? Arterioscler Thromb Vasc Biol 2005; 25: 265-266.
16. Ferroni P, Riandino S, Vazzana N, et al. Biomarkers of platelet activation in acute coronary syndromes. Thromb Haemost 2012; 108: 1109-1123.
17. Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494.
18. Davì G, Guagnano MT, Ciabattoni G, et al. Platelet activation in obese women: role of inflammation and oxidant stress. J Am Med Assoc 2002; 288: 2008-2014.
19. Patrono C, Falco A, Davì G. Isoprostane formation and inhibition in atherothrombosis. Curr Opin Pharmacol 2005; 5: 198-203.
20. Basili S, Pacini G, Guagnano MT, et al. Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol 2006; 48: 2531-2538.
21. Santilli F, Vazzana N, Liani R, et al. Platelet activation in obesity and metabolic syndrome. Obes Rev 2012; 13: 27-42.
22. Santilli F, Basili S, Ferroni P, et al. CD40/CD40L system and vascular disease. Intern Emerg Med 2007; 2: 256-268.
23. Santilli F, Vazzana N, Bucciarelli LG, et al. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr Med Chem 2009; 16: 940-952.
24. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117: 743-753.
25. Wang Z, Ciabattoni G, Créminon C, et al. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. J Pharmacol Exp Ther 1995; 275: 94-100.
26. Ciabattoni G, Pugliese F, Davi G, et al. Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. Biochim Biophys Acta 1989; 992: 66-70.
27. Davì G, Averna M, Catalano I, et al. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation 1992; 85: 1792-1798.
28. Santilli F, Formoso G, Sbraccia P, et al. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. J Thromb Haemost 2010; 8: 828-837.
29. Varo N, Nuzzo R, Natal C, et al. Influence of pre-analytical and analytical factors on soluble CD40L measurements. Clin Sci (Lond) 2006; 111: 341-347.
30. Davì G, Romano M, Mezzetti A, et al. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation 1998; 17; 97: 953-957.
31. Santilli F, Rocca B, De Cristofaro R, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". J Am Coll Cardiol 2009; 53: 667-677.
32. Barlow CE, Defina LF, Radford NB, et al. Cardiorespiratory fitness and longterm survival in "low-risk" adults. J Am Heart Assoc 2012; 1: e001354.
33. El-Sayed MS, Ali N, El-Sayed Ali Z. Aggregation and activation of blood platelets in exercise and training. Sports Med 2005; 35: 11-22.
34. Gibbs CR, Blann AD, Edmunds E, et al. Effects of acute exercise on hemorheological, endothelial, and platelet markers in patients with chronic heart failure in sinus rhythm. Clin Cardiol 2001; 24: 724-729.
35. Li-Saw-Hee FL, Blann AD, Edmunds E, et al. Effect of acute exercise on the raised plasma fibrinogen, soluble P-selectin and von Willebrand factor levels in chronic atrial fibrillation. Clin Cardiol 2001; 24: 409-414.
36. Ahmadizad S, El-Sayed MS, Maclaren DP. Responses of platelet activation and function to a single bout of resistence exercise and racovery. Clin Hemorheol Microcirc 2006; 25: 159-168.
37. Rauramo I, Ilmonen S, Viinikka L, et al. Prostacyclin and thromboxane in pregnant and nonpregnant women in response to exercise. Obstet Gynecol 1995; 85: 1027-1030.
38. Wennmalm A, Nowalk J, Bjuro T. Excretion of thromboxane A2 and prostacyclin metabolites before and after exercise testing in patients with and without signs of ischemic heart disease. Circulation 1990; 82: 1737-1743.
39. Gangemi S, Luciotti G, D'Urbano E, et al. Physical exercise increases urinary excretion of lipoxin A4 and related compounds. J Appl Physiol 2003; 94: 2237-2240.
40. Li N, Wallen NH, Hjemdahl P. Evidence for prothrombotic effects of exercise and limited protection by aspirin. Circulation 1999; 100: 1374-1379.
41. Stewart JK. Exercise training and the cardiovascular consequences of type diabetes and hypertension: plausible mechanisms for improving cardiovascular health. J Am Med Assoc 2002; 288: 1622-1631.
42. Yoshikawa D Ishii H, Kurebayashi N, et al. Association of cardiorespiratory fitness with characteristics of coronary plaque: Assessment using integrated backscatter intravascular ultrasound and optical coherence tomography. Int J Cardiol 2013; 162: 123-128.
43. Rauramaa R, Salonen JT, Seppanen K et al. Inhibition of platelect aggregability by moderate-intensity physical exercise: a randomized clinical trial in overweight men. Circulation 1986; 74: 939-944.
44. FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 1983; 67: 1174-1177.
45. Patrono C, Ciabattoni G, Pugliese F, et al. Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest 1986; 77: 590-594.
46. Ferroni P, Santilli F, Guadagni F, et al. Contribution of platelet-derived CD40L ligand to inflammation, thrombosis and neoangiogenesis. Curr Med Chem 2007; 14: 2170-2180.
47. Bjornstad HH, Bruvik J, Bjornstad AB, et al. Exercise training decreases plasma levels of soluble CD40 ligand and P-selectin in patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil 2008; 15: 43-48.
48. Campbell PT, Gross MD, Potter JD, et al. Effect of exercise on oxidative stress: a 12-month randomized, controlled trial. Med Sci Sports Exerc 2010; 42: 1448-1453.
49. Choi KM, Han KA, Ahn HJ, et al. Effects of exercise on sRAGE levels and cardiometabolic risk factors in patients with type 2 diabetes: a randomized controlled trial. J Clin Endocrinol Metab 2012; 97: 3751-3758.
50. Vazzana N, Santilli F, Cuccurullo C, et al. Soluble forms or RAGE in internal medicine. Intern Emerg Med 2009; 4: 389-401.
51. Voight BF, Peloso GM, Orho-Melander M. et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012; 380: 572-580.
52. Toth PP, Davidson MH. High-density lipoproteins: marker of cardiovascular risk and therapeutic target. J Clin Lipidol 2010; 4: 359-364.
53. Nofer JR, Walter M, Kehrel B, et al. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinosite-derived second messengers 1, 2-diacylglycerol and inositol 1, 4, 5-tris phosphate. Arterioscler Thromb Vasc Biol 1998; 18: 861-869.
54. Vazzana N, Guagnano MT, Cuccurullo C, et al. Endogenous secretory RAGE in obese women: association with platelet activation and oxidative stress. J Clin Endocrinol Metab 2012; 97: E1726-1730.
55. Sebeková K, Krivošíková Z, Gajdoš M. Total plasma N+-(carboxymethyl)lysine and sRAGE levels are inversely associated with a number of metabolic syndrome risk factors in non-diabetic young-to-middle-aged medication-free subjects. Clin Chem Lab Med 2013; 18: 1-11.
56. Kotani K, Caccavello R, Sakane N, et al. Influence of Physical Activity Intervention on Circulating Soluble Receptor for Advanced Glycation end Products in Elderly Subjects. J Clin Med Res 2011; 3: 252-257.
57. Lakka TA, Lakka HM, Rankinen T, et al. Effect of exercise training on plasma levels of C-reactive protein in healthy adults: the HERITAGE Family Study. Eur Heart J 2005; 26: 2018-2025.
58. Okita K, Nishijima H, Murakami T, et al. Can exercise training with weight loss lower serum C-reactive protein levels? Arterioscler Thromb Vasc Biol 2004; 24: 1868-1873.
59. Vanhees L, Geladas N, Hansen D, et al. Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR. Part II. Eur J Prev Cardiol 2012; 19: 1005-1033.
60. Boden WE, Franklin BA, Wenger NK. Physical Activity and Structured Exercise for Patients With Stable Ischemic Heart Disease. J Am Med Assoc 2013; 309: 143-144.